Lipid Metabolism

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
1
ObicetrapibPhase 11 trial
Active Trials
NCT05972278Active Not RecruitingEst. Oct 2024
Takeda
TakedaTOKYO, Japan
1 program
normal dietary behaviorN/A1 trial
Active Trials
NCT01921075Completed9Est. Dec 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NewAmsterdam PharmaObicetrapib
Takedanormal dietary behavior

Clinical Trials (2)

Total enrollment: 9 patients across 2 trials

NCT05972278NewAmsterdam PharmaObicetrapib

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

Start: Dec 2023Est. completion: Oct 2024
Phase 1Active Not Recruiting
NCT01921075Takedanormal dietary behavior

Physiologic Plasticity of Intramyocardial Lipid Storage

Start: Jan 2010Est. completion: Dec 20119 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space